HMGB1, released from the pyroptotic BRAF-mutant melanoma cells induced by BRAF and MEK inhibitors via caspase-3/GSDME pathway, was proved to enhance the durative immunotherapeutic effects by inducing T-cell proliferation and infiltration, which might be a potential strategy against tolerance of both BRAF and MEK inhibitors in patients with BRAF-mutant melanoma (Erkes et al., 2020). The gene discussed is MAP2K7; the disease is melanoma.